Orodispersible

Budesonide orodispersible tablets maintain EoE remission

SAN DIEGO — Patients receiving budesonide orodispersible tablets for the treatment of eosinophilic esophagitis were able to maintain remission through 48 weeks, according to study results presented at Digestive Disease...

Read more
Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-controlled Trial

[ad_1] Swallowed topical-acting corticosteroids are recommended as first-line therapy for eosinophilic esophagitis (EoE). Asthma medications not optimized for esophageal delivery are sometimes effective, although given off label. We performed a...

Read more